Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa

A pilot study

Tommaso Gobello, Cinzia Mazzanti, Donatella Sordi, Giorgio Annessi, Damiano Abeni, Luca M. Chinni, Giampiero Girolomoni

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background: There is currently no definitive cure for urticaria pigmentosa (UP). Psoralen plus ultraviolet A therapy is efficacious in alleviating symptoms and reducing cutaneous lesions. Objective: The purpose of this study was to assess the effect of ultraviolet A1 (UVA1) in adult patients with UP and to compare the effectiveness of high-dose (130 J/cm2/day for 10 days) and medium-dose (60 J/cm2/day for 15 days) UVA1 radiation. Methods: Ten and 12 adult patients with UP were treated with high-dose or medium-dose UVA1, respectively. The number of skin lesions and dermal mast cells, the presence of Darier's sign, the intensity of pruritus, and quality of life measures were evaluated before, at the end of treatment, and 2 and 6 months later. Results: Baseline characteristics were similar among the 2 groups of patients. In the majority of patients, the number of lesions was not significantly reduced. However, the number of mast cells in lesional skin decreased markedly in most patients by the end of treatment, and it remained low for the whole study period. Pruritus and quality of life improved considerably by the end of treatment, and the improvement was maintained during the 6-month follow up. No significant differences were observed between patients receiving high- or medium-dose UVA1. Conclusions: UVA1 phototherapy ameliorates both objective and subjective symptoms of adult patients with UP and induces long-term remission in most cases. Medium-dose UVA1 appears at least as effective as high-dose UVA1.

Original languageEnglish
Pages (from-to)679-684
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume49
Issue number4
DOIs
Publication statusPublished - Oct 1 2003

Fingerprint

Ultraviolet Therapy
Urticaria Pigmentosa
Skin
Pruritus
Mast Cells
Quality of Life
PUVA Therapy
Phototherapy
Therapeutics
Radiation

ASJC Scopus subject areas

  • Dermatology

Cite this

Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa : A pilot study. / Gobello, Tommaso; Mazzanti, Cinzia; Sordi, Donatella; Annessi, Giorgio; Abeni, Damiano; Chinni, Luca M.; Girolomoni, Giampiero.

In: Journal of the American Academy of Dermatology, Vol. 49, No. 4, 01.10.2003, p. 679-684.

Research output: Contribution to journalArticle

@article{fdb1810557014290b7fa5efeace6b66f,
title = "Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: A pilot study",
abstract = "Background: There is currently no definitive cure for urticaria pigmentosa (UP). Psoralen plus ultraviolet A therapy is efficacious in alleviating symptoms and reducing cutaneous lesions. Objective: The purpose of this study was to assess the effect of ultraviolet A1 (UVA1) in adult patients with UP and to compare the effectiveness of high-dose (130 J/cm2/day for 10 days) and medium-dose (60 J/cm2/day for 15 days) UVA1 radiation. Methods: Ten and 12 adult patients with UP were treated with high-dose or medium-dose UVA1, respectively. The number of skin lesions and dermal mast cells, the presence of Darier's sign, the intensity of pruritus, and quality of life measures were evaluated before, at the end of treatment, and 2 and 6 months later. Results: Baseline characteristics were similar among the 2 groups of patients. In the majority of patients, the number of lesions was not significantly reduced. However, the number of mast cells in lesional skin decreased markedly in most patients by the end of treatment, and it remained low for the whole study period. Pruritus and quality of life improved considerably by the end of treatment, and the improvement was maintained during the 6-month follow up. No significant differences were observed between patients receiving high- or medium-dose UVA1. Conclusions: UVA1 phototherapy ameliorates both objective and subjective symptoms of adult patients with UP and induces long-term remission in most cases. Medium-dose UVA1 appears at least as effective as high-dose UVA1.",
author = "Tommaso Gobello and Cinzia Mazzanti and Donatella Sordi and Giorgio Annessi and Damiano Abeni and Chinni, {Luca M.} and Giampiero Girolomoni",
year = "2003",
month = "10",
day = "1",
doi = "10.1067/S0190-9622(03)01483-X",
language = "English",
volume = "49",
pages = "679--684",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa

T2 - A pilot study

AU - Gobello, Tommaso

AU - Mazzanti, Cinzia

AU - Sordi, Donatella

AU - Annessi, Giorgio

AU - Abeni, Damiano

AU - Chinni, Luca M.

AU - Girolomoni, Giampiero

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Background: There is currently no definitive cure for urticaria pigmentosa (UP). Psoralen plus ultraviolet A therapy is efficacious in alleviating symptoms and reducing cutaneous lesions. Objective: The purpose of this study was to assess the effect of ultraviolet A1 (UVA1) in adult patients with UP and to compare the effectiveness of high-dose (130 J/cm2/day for 10 days) and medium-dose (60 J/cm2/day for 15 days) UVA1 radiation. Methods: Ten and 12 adult patients with UP were treated with high-dose or medium-dose UVA1, respectively. The number of skin lesions and dermal mast cells, the presence of Darier's sign, the intensity of pruritus, and quality of life measures were evaluated before, at the end of treatment, and 2 and 6 months later. Results: Baseline characteristics were similar among the 2 groups of patients. In the majority of patients, the number of lesions was not significantly reduced. However, the number of mast cells in lesional skin decreased markedly in most patients by the end of treatment, and it remained low for the whole study period. Pruritus and quality of life improved considerably by the end of treatment, and the improvement was maintained during the 6-month follow up. No significant differences were observed between patients receiving high- or medium-dose UVA1. Conclusions: UVA1 phototherapy ameliorates both objective and subjective symptoms of adult patients with UP and induces long-term remission in most cases. Medium-dose UVA1 appears at least as effective as high-dose UVA1.

AB - Background: There is currently no definitive cure for urticaria pigmentosa (UP). Psoralen plus ultraviolet A therapy is efficacious in alleviating symptoms and reducing cutaneous lesions. Objective: The purpose of this study was to assess the effect of ultraviolet A1 (UVA1) in adult patients with UP and to compare the effectiveness of high-dose (130 J/cm2/day for 10 days) and medium-dose (60 J/cm2/day for 15 days) UVA1 radiation. Methods: Ten and 12 adult patients with UP were treated with high-dose or medium-dose UVA1, respectively. The number of skin lesions and dermal mast cells, the presence of Darier's sign, the intensity of pruritus, and quality of life measures were evaluated before, at the end of treatment, and 2 and 6 months later. Results: Baseline characteristics were similar among the 2 groups of patients. In the majority of patients, the number of lesions was not significantly reduced. However, the number of mast cells in lesional skin decreased markedly in most patients by the end of treatment, and it remained low for the whole study period. Pruritus and quality of life improved considerably by the end of treatment, and the improvement was maintained during the 6-month follow up. No significant differences were observed between patients receiving high- or medium-dose UVA1. Conclusions: UVA1 phototherapy ameliorates both objective and subjective symptoms of adult patients with UP and induces long-term remission in most cases. Medium-dose UVA1 appears at least as effective as high-dose UVA1.

UR - http://www.scopus.com/inward/record.url?scp=0141533250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141533250&partnerID=8YFLogxK

U2 - 10.1067/S0190-9622(03)01483-X

DO - 10.1067/S0190-9622(03)01483-X

M3 - Article

VL - 49

SP - 679

EP - 684

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -